Emil Kuriakose - 01 Oct 2025 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role: Chief Medical Officer
Signature: /s/ David Strauss, as Attorney-in-Fact for Emil Kuriakose
Issuer symbol: TERN
Transactions as of: 01 Oct 2025
Net transactions value: -$7,407
Form type: 4
Filing time: 02 Oct 2025, 19:24:36 UTC
Previous filing: 03 Jul 2025
Next filing: 06 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kuriakose Emil	Chief Medical Officer	C/O TERNS PHARMACEUTICALS, INC., 1065 E. HILLSDALE BLVD., SUITE 100, FOSTER CITY	/s/ David Strauss, as Attorney-in-Fact for Emil Kuriakose	02 Oct 2025	0001892413

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TERN	Common Stock	Sale	$7,407	-944	-1.8%	$7.85	51,520	01 Oct 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person.
F2	This sale price represents the weighted average sale price of the shares sold ranging from $7.74 to $7.91 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Content

Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person.

This sale price represents the weighted average sale price of the shares sold ranging from $7.74 to $7.91 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.